Sessions
The Next Wave: Cell and Gene Therapy’s Commercial Shift
Scaling Up and Out – Drastically Upsizing or Upscaling Your Cell and Gene Therapies
Building Better Cell Therapy Processes
Operational Excellence for Advanced Therapies
Building Better Quality Products: Quality Control and Assurance
Building Robust Manufacturing Processes for Gene Therapies
Getting to Commercial Manufacturing: Producing Therapies for Patient Need
Accelerating Clinical Manufacturing: Progressing Novel Therapeutics
The Next Wave: Cell and Gene Therapy’s Commercial Shift
19 Jan 2023
15:30
Manufacturing Advanced Therapies Track
SPONSORED BY
15:30pm Chair Introduction
Matthew Hewitt, Executive Director Scientific Services, Cell and Gene Therapy, Charles River Laboratories
15:35am Presentation: Pioneering a New Wave of Gene-Agnostic Gene Therapy
- Recent advancements in gene therapy
- Overview of retinal degenerative disease
- Novel, gene-agnostic optogenetics approach to treat retinal degenerative disease
- Clinical program overview and next steps
Samarendra Mohanty, Co-Founder and President, Nanoscope Therapeutics
16:05am Presentation: Present and Future of Cell and Gene Therapies
- Overview of cell therapy progress to date
- Critical technological advancements driving robust development, manufacturing and testing
- Leveraging a discovery platform to engineer a TCR-T cell therapy product to treat AML
- Future direction of the cell therapy industry
Robert Keefe, Chief Development Officer, BlueSphere
16:35pm Closing Panel with Q&A
With all session participants
Speakers
